Allakos Inc (ALLK)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Robert Alexander
Employees:
190
75 SHOREWAY ROAD, SUITE A, SAN CARLOS, CA 94070
650-597-5002

Allakos Inc. develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of gastritis and/or eosinophilic duodenitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.

Data derived from most recent annual or quarterly report
Market Cap 614.318 Million Shares Outstanding85.204 Million Avg 30-day Volume 746.159 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.11
Price to Revenue0.0 Debt to Equity0.0 EBITDA-361.864 Million
Price to Book Value1.0343 Operating Margin0.0 Enterprise Value30.674 Million
Current Ratio12.295 EPS Growth-0.635 Quick Ratio11.792
1 Yr BETA 1.4293 52-week High/Low 8.73 / 2.54 Profit Margin0.0
Operating Cash Flow Growth-68.783 Altman Z-Score-2.1465 Free Cash Flow to Firm -260.517 Million
Earnings Report2023-02-28
View SEC Filings from ALLK instead.

View recent insider trading info

Funds Holding ALLK (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALLK

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-29:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-10:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-19:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-12:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-05:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-25:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-21:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-27:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    RADFORD HARLAN BAIRD CHIEF FINANCIAL OFFICER

    • Officer
    593,045 2023-01-06 5

    ALEXANDER ROBERT CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    1,839,319 2023-01-06 6

    TOMASI ADAM PRESIDENT

    • Officer
    1,049,158 2023-01-06 6

    PATERSON CRAIG A. CHIEF MEDICAL OFFICER

    • Officer
    529,902 2023-01-06 5

    JANNEY DANIEL

    • Director
    • 10% Owner
    9,050,493 2022-09-21 2

    WALKER PAUL EDWARD

    • Director
    6,147,260 2022-09-21 2

    FITZGERALD MARGARET NELL GENERAL COUNSEL AND SECRETARY

    • Officer
    153,128 2022-09-02 4

    LADD AMY L

    • Director
    0 2022-07-21 2

    MCKEARN JOHN P

    • Director
    99,590 2022-05-25 1

    JAMES STEVEN P

    • Director
    99,590 2022-05-25 1

    ANDREATTA ROBERT E

    • Director
    99,590 2022-05-25 1

    ASBURY MARK CLO

    • Officer
    • GC AND SECRETARY
    228,615 2022-02-25 1

    RASMUSSEN HENRIK S MD CHIEF MEDICAL OFFICER

    • Officer
    98,550 2021-06-03 0

    HOLLES NATALIE C.

    • Director
    7,700 2021-05-25 0

    HUDSON PETER A

    • MEMBER - POTENTIAL 10% GROUP
    2,079,147 2021-03-09 0

    NOHRA GUY P

    • 10% Owner
    6,448,053 2021-03-04 0

    MORE ROBERT J

    • MEMBER - POTENTIAL 10% GROUP
    2,071,147 2021-03-03 0

    RIVERVEST VENTURE FUND III, L.P.

    RIVERVEST VENTURE FUND II (OHIO), L.P.

    RIVERVEST VENTURE FUND III (OHIO), L.P.

    RIVERVEST VENTURE FUND II L P

    3X5 RIVERVEST FUND II, L.P.

    3X5 RIVERVEST FUND II-B, L.P.

    • 10% Owner
    No longer subject to file 2021-01-04 0

    ALTA PARTNERS NEXTGEN FUND I MANAGEMENT, LLC

    ALTA PARTNERS VIII, L.P.

    ALTA PARTNERS MANAGEMENT VIII, LLC

    ALTA PARTNERS NEXTGEN FUND I, L.P.

    • 10% Owner
    8,519,200 2021-01-04 0

    REDMOND LEO CHIEF FINANCIAL OFFICER

    • Officer
    51,958 2020-12-01 0

    ALTA PARTNERS NEXTGEN FUND I MANAGEMENT, LLC

    ALTA PARTNERS MANAGEMENT VIII, LLC

    ALTA PARTNERS NEXTGEN FUND I, L.P.

    CHAMPSI FARAH

    HUDSON PETER A

    MORE ROBERT J

    NOHRA GUY P

    ALTA PARTNERS VIII, L.P.

    JANNEY DANIEL

    • Director
    • 10% Owner
    10,549,114 2020-01-22 2

    ROCHE HOLDING LTD

    ROCHE FINANCE LTD

    • 10% Owner
    4,610,723 2018-07-23 0

    ALTA PARTNERS VIII, L.P.

    ALTA PARTNERS MANAGEMENT VIII, LLC

    ALTA PARTNERS NEXTGEN FUND I MANAGEMENT, LLC

    ALTA PARTNERS NEXTGEN FUND I, L.P.

    CHAMPSI FARAH

    HUDSON PETER A

    MORE ROBERT J

    NOHRA GUY P

    • 10% Owner
    22,788,400 2018-07-23 0

    REDMILE GROUP, LLC

    GREEN JEREMY

    • 10% Owner
    No longer subject to file 2018-07-23 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    ALEXANDER ROBERT - Director - Officer CHIEF EXECUTIVE OFFICER

    2023-01-09 18:15:10 -0500 2023-01-06 A 301,575 a 1,056,694 direct 0.2692 6.5949 9.1521 5 0.0 1

    ALEXANDER ROBERT - Director - Officer CHIEF EXECUTIVE OFFICER

    2023-01-09 18:15:10 -0500 2023-01-06 A 462,325 a 462,325 direct

    PATERSON CRAIG A. - Officer CHIEF MEDICAL OFFICER

    2023-01-09 18:15:14 -0500 2023-01-06 A 102,690 a 372,474 direct 0.2692 6.5949 9.1521 5 0.0 1

    PATERSON CRAIG A. - Officer CHIEF MEDICAL OFFICER

    2023-01-09 18:15:14 -0500 2023-01-06 A 157,428 a 157,428 direct

    TOMASI ADAM - Officer PRESIDENT

    2023-01-09 18:15:18 -0500 2023-01-06 A 195,997 a 744,734 direct 0.2692 6.5949 9.1521 5 0.0 1

    TOMASI ADAM - Officer PRESIDENT

    2023-01-09 18:15:18 -0500 2023-01-06 A 300,471 a 300,471 direct

    RADFORD HARLAN BAIRD - Officer CHIEF FINANCIAL OFFICER

    2023-01-09 18:15:22 -0500 2023-01-06 A 126,640 a 398,901 direct 0.2692 6.5949 9.1521 5 0.0 1

    RADFORD HARLAN BAIRD - Officer CHIEF FINANCIAL OFFICER

    2023-01-09 18:15:22 -0500 2023-01-06 A 194,144 a 194,144 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ALLAKOS INC ALLK 2023-02-03 22:15:03 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 21:45:03 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 21:15:03 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 20:45:06 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 20:15:04 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 19:45:03 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 19:15:04 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 18:45:03 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 18:15:03 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 17:45:03 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 17:15:04 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 16:45:04 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 16:15:03 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 15:45:03 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 15:15:03 UTC 4.0719 0.4981 1500000
    ALLAKOS INC ALLK 2023-02-03 14:45:04 UTC 3.9072 0.4128 1500000
    ALLAKOS INC ALLK 2023-02-03 14:15:04 UTC 3.9072 0.4128 1500000
    ALLAKOS INC ALLK 2023-02-03 13:45:03 UTC 3.9072 0.4128 1500000
    ALLAKOS INC ALLK 2023-02-03 13:15:03 UTC 3.9072 0.4128 1500000
    ALLAKOS INC ALLK 2023-02-03 12:45:03 UTC 3.9072 0.4128 1400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Trust for Professional Managers- Convergence Market Neutral Fund ALLK -736.0 shares, $-65930.88 2020-08-31 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity Fund ALLK -407.0 shares, $-31888.45 2021-11-30 N-PORT
    FundVantage Trust- Gotham Hedged Plus Fund ALLK -785.0 shares, $-4804.2 2022-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments